Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)

Next Previous
Trial Profile

A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Tafasitamab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms L-MIND
  • Sponsors MorphoSys

    • Most Recent Events

    • 29 Feb 2024 According to a Knight Therapeutics media release, company announced hat the launch of Minjuvi (tafasitamab) by Brazilian affiliate, United Medical Ltda. for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, including DLBCL arising from low grade lymphoma, not eligible for autologous stem cell transplant (ASCT). The marketing authorization was based on the data from L-MIND study.
    • 16 Oct 2023 According to a Knight Therapeutics media release, announced today that its Brazilian affiliate, United Medical Ltd., has received pricing approval for Minjuvi (tafasitamab) from the Drugs Market Regulation Chamber based on the approval of data from L-MIND and company expects to launch Minjuvi in Brazil in the second quarter of 2024.
    • 27 Jun 2023 According to Specialised Therapeutics Asia Media Release, The Therapeutic Goods Administration (TGA) has provisionally approved MINJUVI (tafasitamab) in combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top